FDA's Woodcock Expresses Concern Not All Generics Are Equivalent, But OGD May Have Solution
Executive SummaryIt didn't seem like deliberate choice to play good cop-bad cop, but Acting Office of Generic Drugs Director Keith Webber and Center for Drug Evaluation and Research Director Janet Woodcock offered a near textbook version of it at the recent Generic Pharmaceutical Association Fall Technical Conference.
You may also be interested in...
A cluster of complaints in one area may inform a new safety signal or other problem, agency official says.
Sen. Cassidy does not think additional appropriations are needed for a massive provider and patient education on biosimilars.